The content on this site is intended for healthcare professionals only

For the latest ecancer COVID-19 resources, click on this link

Breast

Prostate & urology

Lung & pleura

Colorectal & gastro

Melanoma & skin

Head & neck

Ovary & gynaecology

+ -

Cetuximab for NSCLC, from ASCO 2008

2009 ASCO Annual Meeting

29 May - 2 Jun 2009

Published: 27 Nov 2008

Views: 15772

Rating:

Save

Professor Nicholas Thatcher

Categories:
Lung & pleura

Related Videos

Latest in diagnostics in EGFR mutated NSCLC

Dr Neal Lindeman - Brigham and Women's Hospital, Boston, USA

Latest in diagnostics in EGFR mutated NSCLC ( Dr Neal Lindeman - Brigham and Women's Hospital, Boston, USA )

WCLC 2021: Epidemiology of MET Exon 14 mutations

Dr Anna Minchom, Dr Alex Spira, Prof Byoung Chul Cho and Prof Albrecht Stenzinge...

WCLC 2021: Epidemiology of MET Exon 14 mutations ( Dr Anna Minchom, Dr Alex Spira, Prof Byoung Chul Cho and Prof Albrecht Stenzinger )

ESMO 2021: Latest in EGFR mutated advanced NSCLC

Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera

ESMO 2021: Latest in EGFR mutated advanced NSCLC ( Dr Anna Minchom, Prof Natasha Leighl, Dr Victor Moreno and Dr Carlos Cabrera )

First-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and br...

Dr David Paul Carbone - The Ohio State University Medical Center, Ohio, USA

First-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and brain metastases: Results From CheckMate 9LA ( Dr David Paul Carbone - The Ohio State University Medical Center, Ohio, USA )

Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK

Challenges in first line ALK+ NSCLC and emerging data on ALK TKIs ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuva...

Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron Institute...

IMpower010: A Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC ( Dr Enriqueta Felip - Vall d’Hebron University Hospital & Vall d’Hebron Institute of Oncology, Barcelona, Spain )

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity

Dr Danny Nguyen - City of Hope, Orange County, USA

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicity ( Dr Danny Nguyen - City of Hope, Orange County, USA )

OncoAlert and ecancer - ESMO 2021 Day 3

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 3 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

OncoAlert and ecancer - ESMO 2021 Day 2

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

More from ecancer